AHP1905 recognises Buprenorphine, a semi-synthetic opiate first marketed as an analgesic. It is prescribed for the treatment of moderate to severe pain or for anaesthetic induction. It is available in transdermal patches for long-term treatment of pain not responding to non-opioids. It is also used in opioid dependence treatment as withdrawal symptoms are milder than those of methadone.
AHP1905 cross-reacts only very weakly (<1.2% in all cases) with morphine, morphine-3-glucuronide, 6-monoacetylmorphine, codeine, oxycodone, noroxycodone, hydromorphone, hydrocodone, dihydrocodone and thebaine.
Application
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visitwww.abdserotec.com/protocols.
Application Name
Yes
No
Not Determined
Suggested Dilution
ELISA
11.5ug/ml -
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
